semaglutide 503b FDA Proposes to Exclude GLP-1s From Bulk List 503a semaglutide Compound Safety 503A

This is important because it indicates that any increase in systemic GLP-1 levels (for example through medication) could potentially influence the amount that reaches the joint. Tue Wenzel Kragstrup, MD, PhD The next step (in this research) is to find out whether GLP-1-based drugs reach the joints in high enough concentrations to have biological effects there, Kragstrup continued

Warning: For external use only

This medication requires a prescription and must be used under the guidance of a qualified healthcare professional

We're bringing back nostalgic American classics made better, says co-founder Gabe Zichermann

It's not clear whether daily pills or weekly injections will be preferred by patients

Specifically, first-year discontinuation rates are about 45% for patients with T2DM and 65% for those without (Rodriguez et al., 2025)